Holen Sie sich die Stockscreener-App
98.91
0.38%
-0.38
Handel nachbörslich:
98.91
Schlusskurs vom Vortag:
$99.29
Offen:
$99.21
24-Stunden-Volumen:
1.59M
Relative Volume:
0.74
Marktkapitalisierung:
$19.42B
Einnahmen:
$4.58B
Nettoeinkommen (Verlust:
$870.87M
KGV:
22.49
EPS:
4.3988
Netto-Cashflow:
$945.58M
1W Leistung:
-1.98%
1M Leistung:
-5.31%
6M Leistung:
+44.67%
1J Leistung:
+44.56%
1-Tages-Spanne:
$98.06
$99.28
1-Wochen-Bereich:
$97.63
$101.51
52-Wochen-Spanne:
$53.56
$109.28
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
98.91 | 19.49B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals - MyChesCo
Incyte Corporation (NASDAQ:INCY) Nasdaq Index Fund Pathway Science - Kalkine Media
Incyte Corporation (NASDAQ:INCY) Receives Average Rating of "Hold" from Analysts - MarketBeat
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options - MyChesCo
22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co. - MarketBeat
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pacer Advisors Inc. Grows Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock outperforms competitors on strong trading day - MSN
Is It Too Late To Consider Incyte After A 45% Rally In 2025? - Yahoo Finance
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader - MyChesCo
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte (INCY) Valuation Check After Japan Oncology Approvals for Minjuvi and Zynyz - simplywall.st
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan - Yahoo Finance
Thomas Tray Sells 600 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (NASDAQ:INCY) Insider Sells $277,400.00 in Stock - MarketBeat
Incyte principal accounting officer Tray Thomas sells shares worth $336k - Investing.com
Incyte Corp Principal Accounting Officer Sells Shares - TradingView — Track All Markets
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte (NASDAQ:INCY) Stock Price Down 3.4%Time to Sell? - MarketBeat
Incyte Secures Dual Approvals In Japan For Zynyz And Minjuvi - RTTNews
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer - Kalkine Media
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido - PharmiWeb.com
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer - PharmiWeb.com
Japan Approves Incyte's (INCY) Zynyz for First-Line SCAC Treatme - GuruFocus
Incyte (INCY) Secures Japanese Approval for Minjuvi Combination Therapy - GuruFocus
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
Entry Recap: Can Incyte Corporation stock beat market expectations this quarterJuly 2025 Snapshot & Weekly Top Gainers Trade List - moha.gov.vn
Incyte’s Precision Antibody Delivers Striking Results in Rare Blood Cancer - MyChesCo
VP Iyengar Files To Sell 52,941 Of Incyte Corp [INCY] - TradingView — Track All Markets
Why Incyte Corporation (ICY) stock stays on buy listsMarket Performance Report & High Conviction Buy Zone Alerts - DonanımHaber
Can Incyte Corporation stock hit analyst price targetsWatch List & Free Weekly Watchlist of Top Performers - DonanımHaber
Michael James Morrissey Sells 4,323 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance
First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY) - simplywall.st
Incyte Corp EVP Sells Over $5.6 Million in Company Stock - TradingView — Track All Markets
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - Yahoo Finance
Incyte to Present at Upcoming Investor Conference - Business Wire
EC approves Incyte’s Minjuvi combo for follicular lymphoma - Pharmaceutical Technology
Incyte wins European approval of Minjuvi in FL - The Pharma Letter
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - BioSpace
Incyte's Minjuvi Gets Second Nod From EC For R/R Follicular Lymphoma - Nasdaq
Incyte (INCY) Gains EU Approval for Minjuvi in Follicular Lympho - GuruFocus
Minjuvi approved in EU for relapsed follicular lymphoma treatment - Investing.com
Incyte (INCY) Gains European Approval for Minjuvi in New Cancer Treatment - GuruFocus
Incyte announces EU approval of Xencor-partnered lymphoma therapy - Seeking Alpha
Minjuvi approved in EU for relapsed follicular lymphoma treatment By Investing.com - Investing.com South Africa
INCYTE wins European approval for Minjuvi cancer treatment - StreetInsider
(tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
Is Incyte’s 2025 Surge Justified by Cash Flow Outlook and Oncology Pipeline Progress? - simplywall.st
VP Morrissey Files To Sell 54,008 Of Incyte Corp [INCY] - TradingView — Track All Markets
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.17%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):